Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute phase safety surveillance of Spikevax in high-risk participants with underlying diseases
jRCT2031210095Suspended
- Sponsor
- Takeda
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Takeda. Primary endpoints: Percentage of participants with at least one adverse event, Percentage of participants with specified local reactions at the vaccination site and 1 more. Started Aug 2022; status: suspended.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210095.